HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema].

Abstract
Pimobendan is a positive inotropic agent that dilates blood vessels and sensitizes the myocardium to calcium. We studied the clinical usefulness of single oral doses of pimobendan (2.5 mg) in 8 patients with pulmonary hypertension caused by chronic pulmonary emphysema. We measured the short-term effects of pimobendan on pulmonary hemodynamics and gas exchange. Pimobendan significantly decreased mean pulmonary artery pressure from 23.4 +/- 3.4 to 18.5 +/- 2.5 mmHg, and total pulmonary resistance from 383 +/- 111 to 281 +/- 81 dyne.sec.cm-5, while oxygen delivery and cardiac output increased significantly (oxygen delivery: from 81.8 +/- 10.2 to 93.5 +/- 16.2 ml O2/min. cardiac output: from 4.98 +/- 0.76 to 5.77 +/- 1.49 l/min, means +/- SD). Systemic vascular resistance was not significantly reduced. The ratio of pulmonary to systemic vascular resistance was reduced, but not significantly. Arterial oxygen tension (PaO2) and arterial carbon dioxide tension (PaCO2) did not change significantly. These results indicate that pimobendan may be useful in the treatment of patients with secondary pulmonary hypertension.
AuthorsY Yamazaki, H Matsumoto, A Takeda, T Takahashi, N Sasaki, M Takahashi, T Tsuji, T Fujikane, T Shimizu
JournalNihon Kyobu Shikkan Gakkai zasshi (Nihon Kyobu Shikkan Gakkai Zasshi) Vol. 35 Issue 8 Pg. 847-53 (Aug 1997) ISSN: 0301-1542 [Print] Japan
PMID9366158 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Phosphodiesterase Inhibitors
  • Pyridazines
  • Vasodilator Agents
  • pimobendan
Topics
  • Aged
  • Blood Pressure
  • Cardiac Output
  • Chronic Disease
  • Humans
  • Hypertension, Pulmonary (drug therapy, physiopathology)
  • Male
  • Middle Aged
  • Oxygen Consumption
  • Phosphodiesterase Inhibitors (pharmacology, therapeutic use)
  • Pulmonary Circulation (drug effects)
  • Pulmonary Emphysema (complications, drug therapy, physiopathology)
  • Pyridazines (pharmacology, therapeutic use)
  • Vascular Resistance
  • Vasodilator Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: